Core Viewpoint - The company, Beijing Baipusais Biotechnology Co., Ltd., is actively expanding its product offerings in the fields of cell immunotherapy and recombinant proteins, while benefiting from the depreciation of the RMB and being recognized as a "specialized, refined, distinctive, and innovative" enterprise. Group 1: Company Developments - The company has launched a specific antibody targeting the CD19 antigen in CAR-T cell therapy, enhancing detection methods and expanding its product range related to cell and gene therapy [2] - The company has developed high-quality recombinant proteins for various disease targets and biomarkers, supporting the entire process of biopharmaceutical research and production [2] - The company has initiated product development in response to the monkeypox virus, with multiple recombinant proteins, antibodies, and test kits already available [2] Group 2: Recognition and Financial Performance - The company has been recognized as a national-level "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title for small and medium enterprises in China [3] - In the 2024 annual report, the company reported that overseas revenue accounted for 66.46% of total revenue, benefiting from the depreciation of the RMB [4] - For the period from January to September 2025, the company achieved a revenue of 613 million, representing a year-on-year growth of 32.26%, and a net profit of 132 million, with a year-on-year increase of 58.61% [9]
百普赛斯跌0.33%，成交额2.47亿元，近5日主力净流入3304.93万